RESUMEN
Myxomas are the most frequent,cardiac benign cardiac tumors which often present with stroke caused by tumorous orthrombotic emboli.The treatment of embolic stroke due to cardiac myxoma is still a clinical and technical challenge.A 61-year-old man who had an embolic stroke in the left middle cerebral artery was admitted to the Third Poeple's Hospital of Huizhou.The initial National Institutes of Health Stroke Scale (NIHSS) score was 16.He received endovascular thrombectomy after intravenous recombinant tissue plasminogen activator (rt-PA) one hour after stroke onset.No intracranial hemorrhage developed.Pathological study of embolus showed a myxoma.A cardiac mass was found in the left atrium and removed surgically three weeks after stroke.Pathological study of the tumor showed a myxoma.At the one-month follow-up after excision of myxoma,the NIHSS score was 1 and the modified Rankin scale score was 0.No recurrence of embolism occurred after surgical resection.Endovascular thrombectomy after intravenous rt-PA (bridging therapy) for embolic stroke due to cardiac myxoma is safe and effective,and early resection of atrial myxoma can effectively avoid recurrence of cerebral infarction.
RESUMEN
Myxomas are the most frequent, cardiac benign cardiac tumors which often present with stroke caused by tumorous orthrombotic emboli. The treatment of embolic stroke due to cardiac myxoma is still a clinical and technical challenge. A 61-year-old man who had an embolic stroke in the left middle cerebral artery was admitted to the Third Poeple′s Hospital of Huizhou. The initial National Institutes of Health Stroke Scale (NIHSS) score was 16. He received endovascular thrombectomy after intravenous recombinant tissue plasminogen activator (rt-PA) one hour after stroke onset. No intracranial hemorrhage developed. Pathological study of embolus showed a myxoma. A cardiac mass was found in the left atrium and removed surgically three weeks after stroke. Pathological study of the tumor showed a myxoma. At the one-month follow-up after excision of myxoma, the NIHSS score was 1 and the modified Rankin scale score was 0. No recurrence of embolism occurred after surgical resection. Endovascular thrombectomy after intravenous rt-PA (bridging therapy) for embolic stroke due to cardiac myxoma is safe and effective, and early resection of atrial myxoma can effectively avoid recurrence of cerebral infarction.
RESUMEN
Myxomas are the most frequent, cardiac benign cardiac tumors which often present with stroke caused by tumorous orthrombotic emboli. The treatment of embolic stroke due to cardiac myxoma is still a clinical and technical challenge. A 61-year-old man who had an embolic stroke in the left middle cerebral artery was admitted to the Third Poeple′s Hospital of Huizhou. The initial National Institutes of Health Stroke Scale (NIHSS) score was 16. He received endovascular thrombectomy after intravenous recombinant tissue plasminogen activator (rt-PA) one hour after stroke onset. No intracranial hemorrhage developed. Pathological study of embolus showed a myxoma. A cardiac mass was found in the left atrium and removed surgically three weeks after stroke. Pathological study of the tumor showed a myxoma. At the one-month follow-up after excision of myxoma, the NIHSS score was 1 and the modified Rankin scale score was 0. No recurrence of embolism occurred after surgical resection. Endovascular thrombectomy after intravenous rt-PA (bridging therapy) for embolic stroke due to cardiac myxoma is safe and effective, and early resection of atrial myxoma can effectively avoid recurrence of cerebral infarction.
RESUMEN
Objective To study the effect of atorvastatin on serum levels of CRP,IL-6 and TNF-in patients with acute cerebral infarction.Methods 90 patients with acute cerebral infarction from March 2014 to March 2015 in the third people′s hospital of Huizhou were enrolled in the study.The control group received routine symptomatic treatment,and the observation group was treated with rosuvastatin on the basis of routine symptomatic treatment.The levels of serum CRP,IL-6 and TNF-α were observed before and after treatment in the two groups.After treatment,the neurological impairment was evaluated by the National Institutes of Health Stroke Scale (NIHSS),and the therapeutic effects of the two groups were compared.Results After treatment,CRP,TNF-α,IL-6 levels in observation group were (2.66±0.68)mg/L,(11.20±1.21)mg/L,(4.90±0.92)ng/L respectively,while (6.35±1.50)mg/L,(24.93±5.98)mg/L,(9.38±2.01)ng/L in control group.The three indicators of observation group were lower than those in control group,the difference was statistically significant(P<0.05).The NIHSS score of observation group was (2.83±0.51)%,which was lower than that of control group[(6.91±1.21)%],the difference was statistically significant (P<0.05);the total efficiency of observation group was 95.55% (43/45),better than 71.11% in the control group (32/45),the difference was statistically significant (P<0.05).Conclusion Rosuvastatin can effectively reduce the levels of serum inflammatory factors CRP,IL-6 and TNF-α in patients with acute cerebral infarction,and effectively improve the therapeutic effect.